Table 3.
Initial oxygen treatment, % | |
Oxygen supplementation via mask | 25.9% |
Non-invasive ventilation | 2.8% |
Invasive ventilation | 46.9% |
No oxygen needed | 24.4% |
Duration on invasive ventilation (days) (n = 63) | 11.5 ± 10.0 |
Therapeutic interventions, % | |
Antivirals | 68.5% |
Antibiotics | 97.2% |
Tocilizumab | 33.5% |
Convalescent plasma | 44% |
Anakinra | 2% |
Plasma exchange | 18.8% |
Renal replacement therapy | 13.2% |